Alto Neuroscience (NYSE:ANRO) Given Buy Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research note released on Wednesday,Benzinga reports. They currently have a $30.00 price objective on the stock.

A number of other research firms also recently weighed in on ANRO. JonesTrading decreased their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. BTIG Research raised their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. Finally, Robert W. Baird dropped their target price on shares of Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Alto Neuroscience Trading Up 6.0%

Shares of ANRO stock opened at $27.13 on Wednesday. The stock has a 50 day simple moving average of $21.58 and a 200 day simple moving average of $16.74. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. Alto Neuroscience has a 1 year low of $2.12 and a 1 year high of $28.44. The stock has a market cap of $866.74 million, a P/E ratio of -12.44 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.11. On average, research analysts predict that Alto Neuroscience will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Alto Neuroscience in the first quarter worth $52,000. Torren Management LLC bought a new stake in Alto Neuroscience in the fourth quarter worth $62,000. Invesco Ltd. bought a new stake in Alto Neuroscience in the first quarter worth $67,000. Vanguard Personalized Indexing Management LLC lifted its stake in Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.